U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback